David A Sallman, MD

Trials

Studies that name David A Sallman, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 09:16 UTC. Open this list on ClinicalTrials.gov

• Ph1/Ph2
  NCT04798339 · Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESA

  H. Lee Moffitt Cancer Center and Research Institute · active not recruiting · Myelodysplastic Syndromes · principal investigator
• Ph1
  NCT04245397 · Study of SX-682 Alone and in Combination With Oral or Intravenous Decitabine in Subjects With Myelodysplastic Syndrome

  Syntrix Biosystems, Inc. · recruiting · Myelodysplastic Syndromes · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-12 09:16 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.

NIH grants that fund their trials

These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.

• HLS- A Phase 1 Open-Label Dose-Escalation with Expansion Study of SX-682 in MDS Patients
  R44HL142389 · NHLBI · SYNTRIX BIOSYSTEMS, INC. · PI STUART J KAHN, DEAN YOSHIMASA MAEDA · fiscal years 2018 to 2020
  Named on NCT04245397
• A Dose Expansion Study of SX-682 Alone and in Combination with Decitabine in MDS Patients
  R44CA291622 · NCI · SYNTRIX BIOSYSTEMS, INC. · PI Aaron D Schuler, JOHN A ZEBALA · fiscal years 2024 to 2026
  Named on NCT04245397